|
|
| | AE-3763 Basic information |
| Product Name: | AE-3763 | | Synonyms: | AE-3763;1-Imidazolidineacetic acid, 3-[2-[[(1S)-2-methyl-1-[[(2S)-2-[[[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]amino]carbonyl]-1-pyrrolidinyl]carbonyl]propyl]amino]-2-oxoethyl]-2-oxo-;2-(3-(2-(((S)-3-methyl-1-oxo-1-((S)-2-(((S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl)pyrrolidin-1-yl)butan-2-yl)amino)-2-oxoethyl)-2-oxoimidazolidin-1-yl)acetic acid | | CAS: | 291778-77-3 | | MF: | C23H34F3N5O7 | | MW: | 549.54 | | EINECS: | | | Product Categories: | | | Mol File: | 291778-77-3.mol |  |
| | AE-3763 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | color | White to off-white |
| | AE-3763 Usage And Synthesis |
| Uses | AE-3763 is a peptide-based human neutrophil elastase inhibitor with an IC50 of 29 nM. | | in vivo | Edema and leukocytes infiltration into the lung are significantly inhibited by infusion of AE-3763. AE3763 significantly improves survival rate by 24 h in a mouse model of fatal shock associated with multiple organ dysfunction. AE-3763 dose-dependently prevents hemorrhage when given intravenously by infusion (ED50: 0.42 mg/kg/h) or by bolus injection (1.2 mg/kg). With regard to the toxicity of AE-3763 in mice, the results of a preliminary study have shown no overt toxic effect even at the high dose of 300 mg/kg, iv[1]. | | References | [1] Inoue Y, et al. Development of a highly water-soluble peptide-based human neutrophil elastase inhibitor; AE-3763 for treatment of acute organ injury. Bioorg Med Chem. 2009 Nov 1;17(21):7477-86. DOI:10.1016/j.bmc.2009.09.020 |
| | AE-3763 Preparation Products And Raw materials |
|